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CHAPTER I 
 
INTRODUCTION 
 
Cancer 
 Cancer is a term for a group of diseases characterized by unrestrained 
growth and spread of abnormal cells that, if unchecked, can result in death. It is 
the second most common cause of death in the United States, exceeded only by 
heart disease and accounting for nearly 1 of every 4 deaths [1]. Globally, one in 
eight deaths is due to cancer; cancer causes more deaths than AIDS, 
tuberculosis, and malaria combined. This year 1,596,670 Americans will be 
diagnosed with cancer and 571,950 are expected to die from it. In the US, nearly 
1 in 2 men and 1 in 3 women will develop cancer in their lifetime. The 5-year 
relative survival rate for all cancers diagnosed between 1999 and 2006 is 68%, 
an improvement from 50% in 1975-1977 that reflects progress in diagnosing 
certain cancers at an earlier stage and advances in treatment [1]. However, we 
are still far from the goal of eliminating cancer as a major cause of sickness and 
death.  
 
Tumor Progression and Microenvironment 
 The process of malignant transformation, collectively known as tumor 
progression, can be broken up into steps. Each step is driven by mutations that 
activate or inactivate different genes. It is estimated that tumor cells posses 104-
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105 genetic changes [2]. The first step in tumor progression is initiation and 
growth. Here, mutations aberrantly activate genes involved in cell growth and 
division [3]. These genes are termed oncogenes. When functioning properly, 
tumor suppressors recognize improperly activated oncogenes and halt 
inappropriate cell division. However, additional mutations disable tumor 
suppressors, resulting in uncontrolled proliferation and division of normally 
quiescent cells.  
 The next step in tumor progression involves the recruitment and infiltration of 
non-malignant cells into the tumor. Rather than being a homogeneous collection 
of neoplastic cells, tumors also contain many non-malignant cells (Figure 1), [4]. 
Collectively, the cells, both malignant and non-malignant, and the conditions 
within a tumor, i.e. hypoxic, necrotic, etc., comprise the tumor microenvironment 
[5,6]. Fibroblasts and other stromal cells that support tumor growth are recruited 
to the tumor. In a process known as immune surveillance, the host immune 
system recognizes and attempts to halt tumor development [7]. Immune 
inflammatory cells including lymphocytes and monocytes infiltrate into the tumor 
[8]. However, tumors that progress evolve mechanisms to disable or re-program 
the immune cells in order to escape host immune surveillance [7]. 
 Like other normal tissues, tumors need nutrients and oxygen in order to grow 
and divide. Tumors generally cannot grow larger than 1-2 mm without a blood 
supply, due to a lack of oxygen and other nutrients [9]. Thus, gaining access to 
the host vascular system and developing tumor blood vessels is an essential and 
rate-limiting step in tumor growth and progression [10]. The process of blood  
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Figure 1. The tumor microenvironment contains many non-malignant cells. The 
tumor microenvironment refers to the different cell types present in the tumor as well as 
the tumor stroma, blood vessels, secreted molecules and the local conditions within the 
microenvironment (i.e. hypoxic, necrotic, etc.). In addition to malignant tumor cells, 
tumors contain fibroblasts, endothelial cells and pericytes that make up blood vessels, 
and numerous bone marrow-derived immune cells (BMDCs). Immune cells present in 
the tumor microenvironment include lymphocytes, macrophages known as tumor-
associated macrophages (TAMs), neutrophils and myeloid-derived suppressor cells 
(MDSCs). 
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vessel spouting from pre-existing vessels is termed angiogenesis; the induction 
of tumor blood vessel growth is known as the angiogenic switch [10]. Hypoxia 
and other stresses induce tumors to secrete vascular endothelial growth factor 
(VEGF) and other angiogenic stimuli [11]. In response, endothelial cells sprout 
from existing blood vessels, proliferate and migrate towards the stimuli [12]. They 
adhere to one another as they migrate and mature into new vessel structures. 
This process is often disorganized in tumor angiogenesis, resulting in chaotic, 
irregular and leaky tumor blood vessels [13]. Tumor vessels also often lack 
pericytes and are therefore unstable [14].  
 The hypoxic and inflammatory microenvironment within a growing tumor 
applies selective pressure to on tumor cells escape [4,15,16]. Additional 
mutations allow tumor cells to produce matrix metalloproteinases (MMPs) [17] 
and/or to induce MMP production by tumor-associated myeloid-derived 
suprressor cells (MDSCs) [18]. MMPs degrade the basement membrane and 
extracellular matrix, resulting in VEGF and fibroblast growth factor (FGF) release, 
which further stimulates angiogenesis [19]. Additionally, this facilitates the 
escape and local invasion of tumor cells that have acquired motility in a process 
known as epithelial to mesenchymal transition (EMT) [20]. Tumor cells migrate 
along and towards blood vessels, often following a nutrient or oxygen gradient 
[21]. In a process known as intravasation, tumor cells pass between endothelial 
cells and enter the blood or lymphatic circulatory system [22]. Those cells that 
can survive in the blood stream and spread to a secondary site generally reach 
the capillary bed and adhere to the microvessel endothelium [23]. In a reversal of 
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EMT, tumor cells extravasate out of the vessel and colonize the secondary organ 
[24]. Tumor cells that encounter hospitable sites or that can adapt to the new 
microenvironment may to grow into metastases. However, to do so, these cells 
must overcome the same pressures of the primary tumor, i.e. immune evasion 
and angiogenesis [19]. 
 
Myeloid-Derived Suppressor Cells 
 MDSCs which have also been referred to as myeloid immune-suppressor 
cells (MISCs) or myeloid suppressor cells (MSCs), are immature myeloid cells, 
comprised of monocytes/macrophages, granulocytes and dendritic cells (DCs) 
and other myeloid cells at earlier stages of differentiation [25,26]. In mice, 
MDSCs are defined by the simultaneous expression of CD11b (Mac-1), a 
myeloid macrophage/DC marker, and the granulocytic marker Gr-1. Furthermore, 
they lack or have reduced expression of markers of mature myeloid cells, low 
levels of major histocompatibility complex (MHC) class II and co-stimulatory 
molecules and suppress immune responses in vitro and in vivo [25]. Human 
MDSCs are more difficult to define phenotypically since humans lack the Gr-1 
gene. As a result, studies have reported many different markers for human 
MDSCs. However, the consensus is that human MDSCs express the myeloid 
markers CD11b and CD33 with no or minimal expression of myeloid maturation 
markers [27]. MDSCs are increased in various pathological conditions including 
cancer [28]. MDSC accumulation has been documented in the peripheral blood 
of patients with melanoma, head and neck, breast, colon, renal, and non-small 
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cell lung cancers [29]. MDSCs are also significantly increased in the spleens, 
blood and bone marrow of mice bearing large tumors in an assortment of tumor 
models [18]. Furthermore, MDSC production and infiltration into tumors 
increased as tumor size increased and with the duration of tumor growth.  
MDSCs suppress tumor immunity through multiple direct and indirect 
mechanisms, including inhibiting tumor-specific T-cell activation and proliferation 
through the production of arginase [30] and nitric oxide synthase (iNOS) [31]. 
Arginine is a substrate for both of these enzymes and it is also essential for T-cell 
proliferation and activation. Arginine metabolism by arginase and iNOS reduces 
the amount available to T-cells, resulting in T-cell anergy. MDSCs have also 
been demonstrated to suppress Natural Killer (NK) cell cytotoxicity via direct 
contact [32], impair dendritic cell maturation through the production of reactive 
oxygen species [33] and interact with macrophages to effect a tumor-promoting 
type 2 response [34]. MDSCs may also induce regulatory T cells and thereby 
promote immune tolerance of the tumor [35]. As such, the accumulation of 
MDSCs is often associated with poor prognosis. Increased circulating MDSC 
levels were shown to correlate with clinical cancer stage and metastatic tumor 
burden [36]. Gemcitabine treatment to reduce MDSCs enhanced antitumor 
immune activity in tumor bearing mice [37].  
Recently, another tumor-promoting role has been demonstrated for MDSCs in 
tumor angiogenesis. MDSCs from tumor-bearing mice express higher levels of 
matrix metalloproteinase-9 (MMP-9), thereby increasing the bioavailability of 
VEGF [18] and promoting pericyte recruitment, which increases vascular stability 
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[38]. Moreover, MDSCs directly promote tumor angiogenesis by differentiating 
into endothelial cells and directly incorporating into the tumor endothelium in vivo 
[18]. MDSCs have also been implicated in mediating tumor refractoriness to anti-
VEGF treatment [39]. MDSC-produced MMP-9 also enhances tumor cell invasion 
and metastasis [40]. 
 
CCAAT/enhancer binding protein alpha (C/EBPα) 
C/EBPα is the founding member of the CCAAT/enhancer binding protein 
family of transcription factors, all of which bind a similar DNA consensus motif. It 
was first identified as a heat-stable factor in rat liver nuclei that interacted with the 
CCAAT box motif found in some viral promoters. C/EBPα was also 
independently biochemically purified based on its specific interaction with a 
degenerate sequence common to many animal virus enhancers. Reflecting these 
interactions, it was eventually named CCAAT/enhancer binding protein (C/EBP) 
[41]. Upon cloning of the C/EBPα gene, detailed studies resulted in the discovery 
of the basic-leucine zipper (bZIP) class of DNA-binding and dimerization domain 
proteins [42]. Five other C/EBPs, all sharing the highly conserved C-terminal 
basic-leucine zipper domain DNA binding motif, have been identified. The six 
C/EBP family members are identified by Greek letters (α, β, γ, δ, ε, ζ), indicating 
the chronological order of their identification. Members of this family share N-
terminal transactivation domain(s) and the C-terminal bZIP domain, which is 
made up of a basic-amino-acid rich DNA-binding region followed by the leucine 
rich “leucine zipper” dimerization motif. In fact, C/EBP family members share 
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greater than 90% sequence identity in the C-terminal bZIP domain [42]. C/EBPα 
forms homodimers and heterodimers with other C/EBPs as well as other leucine 
zipper transcription factors, including the Fos/Jun and ATF/CREB families [43], to 
precisely modulate the transcription of target genes [44]. Without dimerization 
DNA binding cannot occur and DNA binding specificity results from amino acid 
sequence of the basic region [44]. 
 
The C/EBPα gene 
C/EBPα is encoded as an intronless 2783 base pair gene [45] but two 
C/EBPα isoforms are generated due to utilization of alternate translation start 
codons [46]. C/EBPα is expressed in liver, adipose tissue, intestine, lung, adrenal 
gland, skeletal muscle, pancreas, placenta, prostate gland, mammary gland and 
peripheral blood mononuclear cells in similar levels in the mouse and human 
[44]. In addition to regulating transcription of target genes, C/EBPα has growth-
arresting ability due to its protein-protein interactions and independent of its 
DNA-binding activity [47]. C/EBPα has been shown to interact with numerous cell 
cycle regulators, including p21 [48], Rb [49], E2F [50], and Cdk2 and Cdk4 [51]. 
Thus, C/EBPα is positioned at the crossroads of differentiation and proliferation 
control: it promotes differentiation by the up-regulation of lineage-specific genes 
and limits proliferation through its protein interactions [52,53]. 
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Figure 2. Hematopiesis. The formation of the different cellular components of blood, or 
hematopoiesis, initiates in the bone marrow. Hematopoitic stem cells (HSC) have the 
ability to self-renew and give rise to common lymphoid progenitors (CLP), which produce 
B and T cells, and the common myeloid progenitor (CMP). CMPs further differentiate 
into granulocytes-monocyte progenitors (GMP), which can produce granulocytes and 
monocytes, or megakaryocyte-erythrocyte progenitors (MEP) that can become 
megakaryocytes erythrocytes. 
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Role of C/EBPα in hematopoiesis 
Hematopoiesis, the formation and development of blood, involves the step-
wise acquisition of a specific lineage identity, accompanied by a reduction in self-
renewal capacity (Figure 2) [54]. Within hematopoiesis, C/EBPα is expressed 
predominantly in immature cells, including hematopoietic stem cells (HSC), 
common myeloid progenitors (CMP) and granulocyte-monocyte progenitors 
(GMP) [55]. C/EBPα plays a critical role in regulating the balance between 
proliferation and growth arrest in hematopoietic progenitors [56]. C/EBPα 
accomplishes this by inhibiting differentiation of erythroid cells while promoting 
myeloid differentiation in multipotent progenitor cells [57]. C/EBPα is required for 
the differentiation of bipotential GMPs from multipotential CMPs, as mice lacking 
C/EBPα have normal CMP numbers but lack GMPs and all subsequent stages of 
myeloid differentiation [56]. Once the GMP stage of hematopoiesis has been 
reached however, C/EBPα is no longer required for maturation to more 
differentiated granulocytes and monocytes [58]. C/EBPα has other roles in 
hematopoiesis including regulating hematopoietic stem cell self-renewal [58] and 
directing monocytic development from myeloid progenitors [59]. While C/EBPα 
expression in undetectable in megakaryocyte/erythroid progenitors (MEP) and 
common lymphoid progenitors (CLP), forced expression of C/EBPα in MEPs and 
CLPs redirected them to the myeloid lineage. This revealed that C/EBPα has the 
ability to activate latent myeloid differentiation programs and affect multilineage 
homeostasis [60].  
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C/EBPα target genes 
C/EBPα regulates the expression of the myeloid growth factor receptors, 
macrophage-colony stimulating factor receptor (M-CSFR) [61], interleukin-6 
receptor (IL-6R), granulocyte colony-stimulating factor receptor (G-CSFR) [62] 
and granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR) 
[63,64]. C/EBPα also induces the expression of lactoferin and collagenase, 
neutrophil-specific secondary granule proteins [65], and the microRNA miR-223, 
an important modulator of myeloid differentiation [66].  
 
C/EBPα and cancer 
 Given its important role in hematopoiesis, it is not surprising that mutations 
resulting in the loss of C/EBPα function have been found in acute myeloid 
leukemia (AML). The C/EBPα gene is mutated in 7-9% of all AML cases. 
Additionally, the AML1-ETO fusion protein, found in 12-15% of AML patients, 
appears to suppress C/EBPα expression, and the PML-RARα fusion, which 
blocks myeloid transcription factors including C/EBPα, occurs in 6-7% of AMLs 
[67]. Reduced C/EBPα expression has also been observed in many solid tumors, 
and it has been identified as a tumor suppressor in multiple tissues [68]. 
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Summary and Dissertation Goals 
  
MDSCs play an important role in cancer progression and elucidating the 
mechanisms involved in the accumulation and function of these cells is important 
in the fight against cancer. To that end, a microarray comparing splenic Gr-
1+CD11b+ cells from tumor-bearing mice with tumor-free mice found C/EBPα 
expression was reduced more than 4-fold in the tumor derived cells. Based on 
published reports, we hypothesized that tumors induce MDSC expansion through 
down-regulation of C/EBPα in myeloid cells. In Chapter II, the role of C/EBPα as 
a negative regulator of MDSC expansion was investigated. Deletion of myeloid 
C/EBPα in mice yielded an increase in myeloid progenitors and a reduction in 
mature myeloid cells. Upon inoculation with tumor cells, splenic MDSC 
production was enhanced nearly two-fold in mice lacking C/EBPα in myeloid 
lineage cells, while myeloid progenitor production was reduced, perhaps because 
more progenitors became MDSCs in the absence of C/EBPα. 
In Chapter III, we sought to determine whether C/EBPα is a negative 
regulator of the immune suppressive and pro-angiogenic properties of MDSCs. 
MDSC infiltration and tumor vascularization was significantly greater in C/EBPα 
conditional null mice, resulting in markedly accelerated tumor growth. In an 
experiment where equal numbers of MDSCs were injected with tumor cells into 
mice, C/EBPα ablation resulted in an enhancement in the pro-tumor MDSC 
phenotype: tumor growth and tumor angiogenesis was significantly greater. In 
order to understand the mechanism behind our observations, we measured the 
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expression of genes involved in MDSC-mediated immune suppression and 
angiogenesis. We found that C/EBPα deletion resulted in upregulation of MMP-9, 
VEGF and iNOS expression as well as increased NO production. However, there 
was no difference in arginase expression or immune suppression. Given that NO 
can also regulate angiogenesis, we concluded that C/EBPα does not play a 
major role in MDSC-mediated immune suppression. 
As a whole, our findings reveal dual negative roles for C/EBPα in the 
expansion and pro-angiogenic gene expression in MDSCs and suggest that 
overcoming these functions through C/EBPα inhibition may be a critical step in 
MDSC maturation. Our work indicates that therapy aimed at restoring C/EBPa 
expression in MDSCs may be a viable weapon in the fight against cancer.  
 
  
 
	  
14 
 
CHAPTER II 
 
C/EBPα REGULATES MYELOID DERIVED SUPRESSOR CELL EXPANSION 
 
Abstract 
Myeloid-derived suppressor cells, a population of immature myeloid cells, are 
greatly expanded in cancer patients and tumor-bearing mice. They infiltrate into 
tumors and modulate the tumor microenvironment. In an effort to identify 
molecular mediators responsible for expansion and the tumor-promoting function 
of MDSCs, we discovered C/EBPα expression was significantly reduced in 
MDSCs from tumor-bearing mice compared to non-tumor-bearing hosts. Tumor-
conditioned medium down-regulated C/EBPα expression, suggesting tumor-
secreted factors inhibit the gene expression. Consistent with the function of 
C/EBPα in regulating the balance between proliferation and growth arrest in 
hematopoietic progenitors, myeloid lineage specific deletion of C/EBPα resulted 
in significantly enhanced MDSC proliferation and expansion, as well as an 
increase of myeloid progenitors and a decrease of mature cells. Taken together, 
our results suggest that C/EBPα functions to negatively regulate MDSC 
production and that tumor-induced C/EBPα down-regulation in myeloid lineage 
cells results in MDSC expansion. 
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Introduction 
 
MDSCs are a heterogeneous population of immature myeloid cells that are 
greatly overproduced in numerous human cancer patients MDSCs are also 
systemically expanded in the mice bearing implanted or spontaneous tumors. 
MDSCs are recruited to tumors where they promote tumor growth through 
mechanisms of immune suppression and angiogenesis in the tumor 
microenvironment. As hallmarks of cancer, angiogenesis and immune 
suppression are essential for tumor growth and progression. MDSCs possess 
both tumor-promoting properties and are an intriguing target for cancer therapy. 
While researchers have long observed the dramatic expansion of MDSCs in 
tumor-bearing hosts, the molecular mechanisms regulating MDSC expansion 
under tumor conditions remain less clear. We discovered C/EBPα expression is 
greatly reduced in MDSCs. Given the central role of C/EBPα in regulating 
myeloid differentiation, we hypothesized that C/EBPα is a negative regulator of 
MDSC production and/or function. 
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Materials and Methods 
 
MDSC Isolation 
3LL lung cancer cells or B16 melanoma cells were subcutaneously (s.c.) 
implanted in C57Bl/6 mice for 3 weeks (3LL) or 30 days (B16). After sacrificing 
the mice, tumor tissues were removed and digested with collagenase A and 
hyaluronidase (both from Sigma Aldrich, St. Louis, MO) at 37°C overnight. Single 
cell suspensions were prepared from tumor and spleen tissues. MDSCs were 
isolated by sequential antibody labeling and separation by magnetic column, 
using anti-Gr1-PE (Cat. # 130-091-932) and anti-PE (Cat. # 130-48-801) 
multisort beads, followed by CD11b (Cat. # 130-093-634) MicroBeads (all from 
Miltenyi Biotech, Auburn, CA).  
 
Quantitative RT-PCR 
RNA was isolated from cells using the RNeasy Kit from Qiagen (Cat. no. 
74104, Valencia, CA), according to their protocol. cDNA was synthesized from 1 
µg RNA with the iScript cDNA Synthesis Kit (Cat. # 170-8891, BioRad, Hercules, 
CA) according to the manufacturer’s protocol. For quantitative real time PCR, 
SsoFast EvaGreen Supermix (Cat. # 172-5201, BioRad, Hercules, CA) and a 
CFX96 or MyiQ machine (BioRad, Hercules, CA) were used. The primer 
sequences used for C/EBP-α are ACGGCGGGAACGCAACAACA and 
GAAGATGCCCCGCAGCGTGT, for β-actin: GACAACGGCTCCGGCATGTGC 
and TGGCTGGGGTGTTGAAGGTC. After an initial denaturing (95°C for 2:00), 
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40 cycles of 5 s at 95°C and 9 s at 58.7°C were performed. Target and control 
reactions were performed in triplicate and the average Ct value was calculated. 
Relative changes in transcript levels were determined using the 2–ΔΔCt method 
with β-actin as an internal control. Experiments were repeated three times. 
 
Cell lines 
32D myeloid cell line (# CRL-11346), Lewis lung cancer (3LL) cell line (# 
CRL-1642) and B16 melanoma (# CRL-6475) cell line (all murine, C57BL/6J 
mice) were purchased from ATCC (Manassas, VA). 32D cells were cultured in 
RPMI 1640 + 10% fetal bovine serum (FBS) + 1% penicillin/streptomycin () + 
10% IL-3 Culture Supplement (Cat. # 354040, BD Biosciences, San Jose, CA) at 
37°C, 5% CO2. 3LL cells were grown in RPMI 1640 + 10% FBS + 1% 
penicillin/streptomycin at 37°C, 5% CO2. B16 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) + 10% FBS + 1% penicillin/streptomycin at 
37°C, 5% CO2.  
  
Mice 
C57BL/6J and LysMcre [69] mice were purchased from Jackson Laboratories 
(Bar Harbor, ME). Mice with a floxed Cebpa gene, called Cebpaflox/flox [70], were 
a gift from Peter Johnson (NCI, Frederick, MD). The animals were housed in 
pathogen-free units at the Vanderbilt University Medical Center, in compliance 
with IACUC regulations. We generated mice with myeloid-specific deletion of 
Cebpa by breeding Cebpaflox/flox mice to LysMCre mice, which express Cre 
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recombinase under the control of murine lysozyme M promoter. F1 LysMCre+/-
;Cebpafl/+ were then crossed to produce the genotypes used in the experiments. 
Mice used were between 6 and 10 weeks of age. The studies were approved by 
the Institutional Animal Care and Use Committee at Vanderbilt University Medical 
Center and complied with all relevant institutional and federal guidelines and 
policies.  
 
Tumor allograft model 
B16 or 3LL cells (1 x 105 cells) were injected subcutaneously into the left flank 
of C57Bl/6 mice. The size of tumors was determined by measurement of tumor 
dimensions at 2–3 day intervals using calipers. The equation volume = length x 
(width)2 x 0.5 was used to calculate tumor volume. Tumor samples taken at days 
21 (3LL) or 30 (B16) post-injection were flash frozen in Tissue-Tek OCT (Sakura, 
Torrance, CA) and prepared for histology. Experiments were repeated at least 
three times.  
 
Flow cytometry 
3LL lung cancer cells were implanted subcutaneously in mice for 3 weeks. 
Single cell suspensions from spleens of tumor-bearing mice were labeled with 
florescence-conjugated Gr-1 (Cat. # 553126, monoclonal, rat) and CD11b (Cat. # 
553311, monoclonal, rat) antibodies (BD Biosciences, San Jose, CA) and 
analyzed by flow cytometry using a BD LSRFortessa or BD FACScan. 
 
	  
19 
Proliferation assay 
Cell proliferation was measured by BrdU incorporation using the BD 
Pharmingen FITC BrdU Flow Kit (Cat. # 559619, BD Biosciences, San Jose, 
CA). 3 weeks after subcutaneous implantation of 1 x 105 cells 3LL tumor cells, 
mice were injected intraperitoneally with 2 mg of BrdU 2 hours prior to being 
sacrificed. Single cell suspensions were prepared from the spleens and labeled 
with florescence-conjugated Gr-1 (Cat. # 553126, monoclonal, rat), CD11b (Cat. 
# 553311, monoclonal, rat) and BrdU (Cat. # 559619e, monoclonal, rat) 
antibodies (BD Biosciences, San Jose, CA). BrdU incorporation in the 
Gr1+CD11b+ double-positive MDSC population was measured on a BD 
LSRFortessa cell analyzer. Assay was repeated twice. 
 
Immunohistochemistry 
Cryo-preserved tumor sections were blocked with M.O.M. solution (Vector 
Laboratories, Burlingame, CA), incubated with antibodies to CD31 or Gr-1 (BD 
Biosciences, San Jose, CA; 1:500 dilution or 1:200 dilution, respectively) 
overnight (4° C), and visualized by using Texas Red-conjugated goat anti-rat 2nd 
antibody (Jackson Immuno Research Laboratories, West Grove, PA; 1:10000 
dilution). Images were captured with a fluorescent microscope. Vascular density 
and MDSC infiltration was calculated in 10 randomly selected fields and counted 
in a blinded manner. These experiments were repeated 3 times.  
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Methylcellulose colony assays 
Bone marrow cells were isolated by flushing the tibias and femurs of mice 
with cold IMDM + 2% FBS and pooled from 2-3 mice per group. A single cell 
suspension was prepared and plated in Methocult 3234 methylcellulose semi-
solid medium (Stemcell Technologies, Vancouver, BC) supplemented with 10 
ng/ml IL-3, 10 ng/ml IL-6, and 50 ng/ml stem cell factor (SCF, all from R&D 
Systems, Minneapolis, MN) with and without erythropoietin (StemCell 
Technologies, Vancouver, BC; 3 U/ml). After 7-8 days incubation at 37°C in a 
CO2 incubator, colonies were scored based on cell morphology and colony 
composition under an inverted microscope. Assays were performed in duplicate 
and repeated three times. 
 
Statistical Analysis 
 All data were averaged, analyzed using the Student’s t test (one-sided; 
paired, equal variance) and were expressed as mean ± standard error across 
experiments. 
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Results 
 
C/EBPα is significantly reduced in tumor-derived MDSCs 
MDSCs are vastly overproduced in cancer patients and tumor-bearing 
animals. They infiltrate into tumors and promote tumor growth by promoting 
tumor angiogenesis and immune suppression. To better understand what 
regulates MDSC expansion under tumor conditions, we isolated MDSCs from the 
spleens of C57/BL6 mice with or without Lewis Lung Carcinoma (3LL) tumors by 
magnetic activated cell sorting (MACS). MDSCs were also isolated from the 
tumors of the tumor-bearing mice. We compared C/EBPα expression quantitative 
PCR and found that C/EBPα was significantly reduced in MDSCs isolated from 
tumor-bearing mice compared to controls (Figure 3A). Furthermore, we found 
that C/EBPα expression was nearly undetectable in MDSCs isolated from the 
tumors. 
 
C/EBPα is significantly reduced in myeloid cells cultured under tumor conditions 
 Hypoxia is a hallmark of solid tumors. It promotes tumor growth and 
progression. To test whether hypoxia regulates C/EBPα expression in myeloid 
cells, we cultured 32D murine myeloid cells under hypoxic conditions (1% O2). 
Interestingly, we found that C/EBPα expression was significantly reduced after 4 
hours and even further reduced after 12 hours incubation (Figure 3B). In addition, 
we cultured 32D cells in a mixture of fresh media and medium conditioned by 
3LL tumor cells (TCM). C/EBPα expression was significantly reduced after 4  
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Figure 3. C/EBPα is down-regulated in MDSCs from tumor bearing mice and in 
myeloid cells cultured under tumor conditions. Gr-1+CD11b+ cells were isolated 
from spleens (spln) of C57BL/6 mice with (+) or without 3LL (-) tumors as well as tumor 
tissues (tumor). Gr-1+CD11b+ cells with greater than 95% purity were pooled from 5-7 
mice, RNA was isolated and C/EBPα expression was measured by real-time PCR (A). 
32D cells were cultured under normoxic or hypoxic (1% O2) conditions. RNA was 
isolated and C/EBPα expression was measured by real-time PCR (B). Media was 
collected from 3LL tumor cells after 2-3 days in culture to make tumor-conditioned 
medium (TCM). 32D cells were cultured in a 50:50 mixture of TCM and fresh media for 4 
or 48 hours. RNA was isolated and C/EBPα expression was measured by real-time PCR 
(C). 32D cells were treated with the TNF-α and cultured for 24 hours. RNA was isolated 
and C/EBPα expression was measured by real-time PCR (D). * p < 0.05. The 
experiment was done in triplicate and repeated twice. 
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hours in TCM and longer exposure to TCM further reduced C/EBPα mRNA levels 
(Figure 3C). Furthermore, treatment of 32D cells with the inflammatory cytokine 
TNF-α reduced C/EBPα expression by nearly half (Figure 3D). 
 
Conditional deletion of myeloid C/EBPα increases MDSC expansion under tumor 
conditions 
Based on the critical role of C/EBPα in regulating the balance between 
proliferation and growth arrest in hematopoietic progenitors [56], as well as the 
down regulation of C/EBPα in tumor derived MDSCs (Figure 3A), we suspected 
an inhibitory function for C/EBPα in MDSC expansion and tumor promotion. To 
test the hypothesis in vivo, we utilized a system of conditional myeloid-lineage 
gene deletion. C/EBPα was deleted in cells of the myeloid lineage by breeding 
Cebpaflox/flox mice with LysMCre mice, which express Cre recombinase under the 
control of a murine lysozyme M promoter. Murine lysozyme M is exclusively 
expressed in cells of the monocyte/macrophage and granulocyte lineages of 
hematopoietic differentiation [71] and its expression correlates with myeloid 
maturation, progressively increasing during myeloid differentiation [72]. 
The conditional deleted mice are healthy, fertile and grossly normal. We 
isolated Gr1+CD11b+ MDSCs from the spleens of wild-type littermates and 
Cebpaflox/flox;LysMCre+/+ conditional null mice and confirmed C/EBPα deletion by 
real-time RT-PCR. In this system, C/EBPα was ablated in approximately 75% of 
the Gr1+CD11b+ MDSCs (Figure 4A). This reduction in C/EBPα mRNA levels 
was similar to what was observed in MDSCs isolated from tumor tissues (Figure  
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Figure 4. MDSC expansion and proliferation is greater in C/EBPα conditional null 
tumor-bearing mice. (A) Gr-1+CD11b+ cells were magnetically purified from spleens of 
C/EBPαflox/flox (WT) and C/EBPαflox/flox;LysMCre (CN) mice, RNA was isolated and 
C/EBPα expression was analyzed by semi-quantitative PCR. Wild-type (C/EBPαflox/flox) 
and myeloid conditional null (C/EBPαflox/flox;LysMCre) mice were injected with 1x 105 3LL 
or B16 tumor cells in the hindlimb. After 21 days, spleens were isolated from the mice, 
processed into single-cell suspensions and stained with Gr-1 and CD11b fluorescent 
antibodies. The percentage of Gr-1+CD11b+ cells was analyzed by flow cytometry (B). 2 
hours prior to sacrifice, the tumor bearing mice were injected with BrdU and BrdU 
incorporation was measured in the Gr-1+CD11b+ cells by flow cytometry (C). * p < 0.05. 
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3A). Next we examined the role of C/EBPα in MDSC expansion under tumor 
conditions. We injected 3LL tumor cells subcutaneously (s.c.) into the flanks of 
Cebpaflox/flox;LysMCre+/+ (CN) and Cebpaflox/flox;LysMCre-/- (WT) litter mates for 
several weeks. Single cells suspensions from the spleens of mice with similar 
sized tumors were stained with anti-Gr-1 and anti-CD11b antibodies. Flow 
cytometry analysis revealed a significant increase in Gr1+CD11b+ MDSCs in 
tumor-bearing C/EBPα conditional null mice (CN) compared to littermate controls 
(WT) (Figure 4B).  
 
 
Conditional deletion of myeloid C/EBPα enhances MDSC proliferative capacity 
Given that C/EBPα inhibits proliferation in myeloid progenitors [73], we 
wondered if proliferation was greater in MDSCs from C/EBPα conditional null 
mice. Prior to sacrificing the mice, mice bearing similar sizes of tumors were 
injected intra-peritoneally (i.p.) with BrdU. Flow cytometry analysis revealed that 
BrdU incorporation in MDSCs from Cebpaflox/flox;LysMCre+/+ mice was nearly 
double that of littermate control MDSCs (Figure 4C). These data suggest that 
C/EBPα inhibits MDSC expansion, likely through inhibition of cell proliferation, 
and tumor conditions resulted in an expansion of MDSCs through down 
regulation of C/EBPa in myeloid cells. 
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Conditional deletion of myeloid C/EBPα increases myeloid progenitors 
 Next, we attempted to determine the mechanism of C/EBPα in MDSC 
expansion. C/EBPα is known to inhibit proliferation and induce differentiation of 
myeloid progenitors [57]. Since MDSCs are immature myeloid cells, and deletion 
of C/EBPα led to an increase of MDSCs in vivo, it suggests a role of this 
transcription factor in myeloid cell maturation. To test the hypothesis, colony-
forming unit (CFU) assays in semi-solid methylcellulose medium were performed. 
Single cell suspensions were prepared from bone marrow of 
Cebpaflox/flox;LysMCre+/+ mice and Cebpaflox/flox;LysMCre-/- littermate controls and 
cultured in methylcellulose for about a week. We observed a significant increase 
in the total number of colonies in bone marrow isolated from C/EBPα conditional 
null mice (Figure 5A,B). The number of multi-potential progenitor (CFU-GEMM), 
macrophage (CFU-M) and erythroid (BFU-E) progenitor colonies was also 
significantly greater than littermate controls (Figure 5B). Furthermore, in a similar 
CFU assay for GM (granulocyte-monocyte), M (monocyte) and G (granulocyte) 
progenitors, an increase in the total colony number and in the number and 
percentage of CFU-M progenitor colonies was observed (Figure 5C). 
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Figure 5. Myeloid Progenitors are Increased in C/EBPα Conditional Null Mice. Bone 
marrow was isolated from myeloid conditional null (Cebpaflox/flox;LysMCre+/+, CN) mice 
and Cebpaflox/flox;LysMCre-/- littermate controls (WT). Single cell suspensions were made 
and plated in MethoCult 3434 (A-B) or 3534 (C-D) semi-solid media. After 7-9 days 
incubation, colony types were evaluated and counted using inverted microscope. The 
number of individual colony types (A-D) and total colonies (B) was quantified. Bone 
marrow was pooled from 3 animals and experiments were repeated four times. * p < 
0.05. 
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Conditional deletion of myeloid C/EBPα decreases circulating monocytes 
We also analyzed the effect of myeloid-lineage C/EBPα ablation on circulating 
blood cells by performing complete blood counts (CBCs) on peripheral blood 
(Table 1). We found that the number of circulating monocytes was significantly 
decreased in Cebpaflox/flox;LysMCre+/+ mice compared to controls. Other white 
blood cells were also decreased, although these differences did not reach 
statistical significance. Otherwise myeloid conditional null mice were not different 
from their littermate controls or from the normal range for their species, 
consistent with myeloid lineage-specific deletion of C/EBPα. Taken together, 
these findings show that deletion of C/EBPα in myeloid cells yields an increase in 
myeloid progenitors and an accompanying decrease in circulating mature cells. 
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Table 1. Peripheral blood differential counts of myeloid conditional null mice and 
littermate WT mice. Red blood cell (RBC), Hemoglobin (Hgb), Hematocrit (HCT), total 
white blood cell (WBC) and individual WBCs in peripheral blood were determined with 
an automated cell counter (HemaVet 960) in wild-type littermate Cebpaflox/flox;LysMCre-/-, 
(WT) and myeloid conditional null (Cebpaflox/flox;LysMCre+/+, CN) mice. Shown are the 
numbers from 3 mice ± standard deviation. The experiment was repeated twice. 
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Figure 6. Myeloid Progenitors are Reduced in tumor-bearing C/EBPα Conditional 
Null Mice. Bone marrow was isolated from myeloid conditional null 
(Cebpaflox/flox;LysMCre+/+, CN) mice and Cebpaflox/flox;LysMCre-/- littermate controls (WT). 
Single cell suspensions were made and plated in MethoCult 3434 (A-B) semi-solid 
media. After 7-9 days incubation, colony types were evaluated and counted using 
inverted microscope. The number of individual colony types (A-B) and total colonies (B) 
was quantified. Bone marrow was pooled from 3 animals and experiments were 
repeated four times. * p < 0.05. 
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Conditional deletion of myeloid C/EBPα decreases myeloid progenitors in tumor-
bearing mice 
Methylcellulose CFU assays were also performed on bone from tumor-
bearing mice in order to understand the effect of tumor conditions on myeloid 
progenitor proliferation and differentiation and the role C/EBPα plays in that 
process.  We found that tumor conditions significantly reduced the number of 
total colonies (Figure 6A) as well as the number of myeloid progenitors (CFU-M 
and CFU-G) in Cebpaflox/flox;LysMCre+/+ mice relative to control tumor-bearing 
mice. (Figure 6B)  Intriguingly, there was no difference in the percentage of each 
individual colony type between wild-type and CN mice. 
 
Conditional deletion of myeloid C/EBPα increases circulating white blood cells in 
tumor-bearing mice 
Complete blood counts were also performed on tumor-bearing mice (Table 2). 
Cebpaflox/flox;LysMCre+/+ mice had a significantly higher WBC count and 
significantly more eosinophils than wild-type mice. Additionally the percentage of 
lymphocytes was significantly decreased and the percentage of neutrophils was 
significantly increased in tumor-bearing C/EBPα conditional null mice.  
Furthermore, the monocyte percentage was decreased and the basophil 
percentage elevated in peripheral blood from tumor-bearing mice with a myeloid-
lineage deletion of C/EBPα. Taken together, we found that deletion of C/EBPα in 
myeloid lineage cells resulted in decreased myeloid progenitor production and 
increased circulating white blood cells in tumor bearing mice. 
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Table 2. Peripheral blood differential counts of myeloid conditional null mice and 
littermate WT tumor-bearing mice. Red blood cell (RBC), Hemoglobin (Hgb), 
Hematocrit (HCT), total white blood cell (WBC) and individual WBCs in peripheral blood 
were determined with an automated cell counter (HemaVet 960) in wild-type littermate 
Cebpaflox/flox;LysMCre-/-, (WT) and myeloid conditional null (Cebpaflox/flox;LysMCre+/+, CN) 
mice bearing large tumors. Shown are the numbers from 3 mice ± standard deviation. 
The experiment was repeated twice. 
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Discussion 
 
Based on the critical role of C/EBPα in myeloid differentiation [56], we 
hypothesized that C/EBPα plays a negative role in MDSC expansion. We found 
that C/EBPα expression is down-regulated in MDSCs from the spleens of tumor-
bearing mice. Furthermore, C/EBPα expression was nearly undetectable in 
MDSCs from the tumor microenvironment. These results were mirrored and 
confirmed by our in vitro studies. Treatment of myeloid cells with tumor-
conditioned media reduced C/EBPα mRNA in a time-dependent manner, 
suggesting that tumor-produced factors inhibit C/EBPα expression.  
One such tumor-derived factor is TNF-α, which we found reduced C/EBPα 
expression in myeloid cells in a concentration-dependent manner. Others have 
shown that TNF-α decreases C/EBPα production by inhibiting the transcription 
and decreasing the stability of C/EBPα mRNA (Figure 7) [74]. TNF-α is an 
inflammatory cytokine produced by both tumor and host cells during tumor 
growth. It has been shown to recruit monocytes to the tumor as well as to 
promote tumor angiogenesis and impair immune surveillance [75]. Thus, TNF-α 
appears to participate in the recruitment of MDSCs from the bone marrow and 
spleen to the tumor, while at the same time down-regulating C/EBPα expression 
in MDSCs. Another long-range signal in the spleen could be IL-6, a cytokine 
produced by tumors or tumor-associated myeloid cells that is involved in MDSC 
expansion. IL-6 has been shown to inhibit C/EBPα transcription by activating 
MYC, which directly binds the CEBPA promoter and represses it (Figure 7) [76]. 
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Figure 7. Diagram of the C/EBPα promoter and known regulatory elements. Soluble 
tumor-derived factors (TDFs) such as the inflammatory cytokines TNF-α, IL-1β and IL-6 
are potential long-range signals responsible for C/EBPα downregulation in MDSCs. 
These signals activate the SP-1 transcription factor, which binds and inhibits the C/EBPα 
promoter. IL-6-induced Myc also represses C/EBPα transcription. Once in the tumor 
microenvironment, these TDFs and hypoxia, signaling through hypoxia-inducible factor 
(HIF-1α), which binds and represses a hypoxia-responsive element (HRE) in the 
C/EBPα promoter, might further reduce C/EBPα expression in MDSCs. Additionally, 
calreticulin (CRT) and TNF-α inhibit C/EBPα mRNA stability and translation, 
respectively. 
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We also found that hypoxia down-regulated C/EBPα expression in myeloid 
cells in a time-dependent manner. Hypoxia is a hallmark of solid tumors and is 
critically important in tumor growth and progression [77]. In addition to promoting 
tumor cell survival and angiogenesis, hypoxia signaling is involved in MDSC 
recruitment and activation. Hypoxia represses C/EBPα transcription in multiple 
cell types [78,79]. The C/EBPα promoter contains a hypoxia-responsive element 
(HRE), which is bound by hypoxia-inducible factor (HIF)-1 alpha and is essential 
for down-regulation of C/EBPα transcription in hypoxia (Figure 7) [78]. 
Additionally, calreticulin (CRT), a chaperone protein normally located in the 
endoplasmic reticulum, but is released into the extracellular matrix during 
hypoxia and other cancer-induced stresses binds C/EBPα mRNA and inhibits its 
translation [80]. In addition to hypoxia, other short-range signals that may down-
regulate C/EBPα in the tumor microenvironment include the cytokines IL-1β and 
GM-CSF, which induce MDSC expansion. These cytokine signaling pathways 
(and TNF-α signaling) converge on the SP1 transcription factor, which is 
overexpressed in many cancers. SP1 directly binds the C/EBPα promoter 
represses it [81]. 
When mice with a conditional deletion of C/EBPα in myeloid-lineage cells 
were inoculated with tumor cells, we observed a significant increase in MDSC 
production in the spleens of those mice. C/EBPα regulates cell-cycle progression 
through many mechanisms including E2F inhibition [82]. We observed nearly a 
two-fold enhancement in the proliferative capacity of MDSCs isolated from tumor-
bearing mice lacking C/EBPα in myeloid lineage cells.  
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 Genetic deletion of C/EBPα results in an increase in immature myeloid cells 
and a complete lack of mature granulocytes [83]. Conditional deletion of C/EBPα 
in myeloid cells our system yielded similar results. We saw an increase in the 
number and percentage of myeloid progenitors in the bone marrow and a 
decrease in the number of circulating monocytes in the peripheral blood of these 
mice. We observed the opposite in tumor-bearing mice: C/EBPα conditional null 
mice had fewer myeloid progenitors in the bone marrow and more circulating 
white blood cells. Importantly, we didn’t observe any difference in the relative 
percentages of the myeloid progenitors. Instead there were fewer total colonies 
and less of each individual progenitor in the bone marrow of C/EBPα conditional 
null tumor-bearing mice. Thus it appears that increased myeloid progenitor 
production in the bone marrow yielded greater MDSC expansion in tumor-
bearing mice. Perhaps the increase in white blood cells observed in the 
peripheral blood of C/EBPα conditional null tumor-bearing mice resulted from 
increased MDSC production and expansion in those mice. Taken together, these 
data support the hypothesis that signals in the tumor microenvironment, including 
hypoxia and TNF-α secretion, down-regulate C/EBPα expression in myeloid 
lineage cells, resulting in MDSC proliferation and expansion. 
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CHAPTER III 
 
C/EBPα REGULATES PRO-ANGIOGENIC FUNCTIONS OF MYELOID-
DERIVED SUPRESSOR CELLS IN THE TUMOR MICROENVIRONMENT 
 
Abstract 
 MDSCs are capable of suppressing tumor immunity through multiple direct 
and indirect mechanisms on T-cells, dendritic cells and natural killer cells. 
MDSCs also directly promote tumor growth through mechanisms of tumor 
angiogenesis. Conditional deletion of C/EBPα in myeloid-lineage cells resulted in 
enhanced MDSC infiltration into tumors and increased tumor angiogenesis, 
resulting in accelerated tumor growth. Deletion of C/EBPα in MDSCs enhanced 
the pro-angiogenic and pro-tumorigenic behavior of these cells by upregulating 
the production of iNOS and nitric oxide, as well as MMP-9 and VEGF. However, 
myeloid lineage specific deletion of C/EBPα did not increase MDSC-mediated 
immune suppression.  
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Introduction 
 Immune suppression and angiogenesis are hallmarks of cancer and are 
necessary for tumor growth and progression [84]. MDSCs posses both tumor-
promoting functions; these cells have long been known to suppress the host 
immune response to cancer. MDSCs also directly promote tumor growth through 
mechanisms of tumor angiogenesis and vasculogenesis. They express higher 
levels of MMP-9, thereby increasing the bioavailability of VEGF [18] and 
promoting pericyte recruitment, which increases vascular stability. As such, 
MDSCs have been reported to mediate tumor refractoriness to anti-VEGF 
treatment by providing and alternative source of VEGF [39]. 
MDSCs from tumor-bearing mice have been shown to directly promote tumor 
angiogenesis and growth [18]. When MDSCs from mice with myeloid-lineage 
ablation of C/EBPα were combined with tumor cells in a co-injection study, tumor 
angiogenesis and growth was further increased. MDSCs promote tumor 
angiogenesis and tumor cell invasion through the production of MMP-9 and 
VEGF [18,40]. The expression of MMP-9 and VEGF was significantly increased 
in MDSCs purified from tumor-bearing C/EBPα conditional null mice.  
The immune suppressive properties of MDSCs are largely due to arginase 
and iNOS activity. These enzymes metabolize L-arginine, thereby reducing its 
availability to T-cells, which require it for activation and proliferation. iNOS 
expression and activity was significantly greater in MDSCs isolated from tumor-
bearing mice with a myeloid-lineage deletion of C/EBPα. However, we did not 
observe any difference in arginase expression between the two groups. 
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Additionally, when C/EBPα was deleted in MDSCs, we observed no change in 
their capacity to suppress antigen-specific T-cell proliferation. Taken together, 
these data suggest that in addition to inhibiting MDSC production, C/EBPα 
negatively regulates the pro-angiogenic functions of MDSCs in the tumor 
microenvironment.  
 
Materials and Methods 
 
MDSC Isolation 
3LL lung cancer cells or B16 melanoma cells were subcutaneously implanted 
in C57Bl/6 mice for 3 weeks (3LL) or 30 days (B16). After sacrificing the mice, 
tumor tissues were removed and digested with collagenase A and hyaluronidase 
(both from Sigma Aldrich, St. Louis, MO) at 37°C overnight. Single cell 
suspensions were prepared from tumor and spleen tissues. MDSCs were 
isolated by sequential antibody labeling and separation by magnetic column, 
using anti-Gr1-PE (Cat. # 130-091-932) and anti-PE (Cat. # 130-48-801) 
multisort beads, followed by CD11b (Cat. # 130-093-634) MicroBeads (all from 
Miltenyi Biotech, Auburn, CA). 
 
Quantitative RT-PCR 
RNA was isolated from cells using the RNeasy Kit from Qiagen (Cat. no. 
74104, Valencia, CA), according to their protocol. cDNA was synthesized from 1 
µg RNA with the iScript cDNA Synthesis Kit (Cat. # 170-8891, BioRad, Hercules, 
CA) according to the manufacturer’s protocol. For quantitative real time PCR, 
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SsoFast EvaGreen Supermix (Cat. # 172-5201, BioRad, Hercules, CA) and a 
CFX96 or MyiQ machine (BioRad, Hercules, CA) were used. The primer 
sequences used for C/EBP-α are ACGGCGGGAACGCAACAACA and 
GAAGATGCCCCGCAGCGTGT, for iNOS (NOS2): 
ACCTTGTTCAGCTACGCCTT and CATTCCCAAATGTGCTTGTC, for VEGF-A: 
CCCGGGCCTCGGTTCCAGA and GCCTGGGACCACTTGGCATGG, for β-
actin: GACAACGGCTCCGGCATGTGC and TGGCTGGGGTGTTGAAGGTC. 
After an initial denaturing (95°C for 2:00), 40 cycles of 5 s at 95°C and 9 s at 
58.7°C were performed. Target and control reactions were performed in triplicate 
and the average Ct value was calculated. Relative changes in transcript levels 
were determined using the 2–ΔΔCt method with β-actin as an internal control. 
Experiments were repeated three times. 
 
Cell lines 
32D myeloid cell line (# CRL-11346), Lewis lung cancer (3LL) cell line (# 
CRL-1642) and B16 melanoma (# CRL-6475) cell line (all murine, C57BL/6J 
mice) were purchased from ATCC (Manassas, VA). 32D cells were cultured in 
RPMI 1640 + 10% fetal bovine serum (FBS) + 1% penicillin/streptomycin () + 
10% IL-3 Culture Supplement (Cat. # 354040, BD Biosciences, San Jose, CA) at 
37°C, 5% CO2. 3LL cells were grown in RPMI 1640 + 10% FBS + 1% 
penicillin/streptomycin at 37°C, 5% CO2. B16 cells were cultured in DMEM + 10% 
FBS + 1% penicillin/streptomycin at 37°C, 5% CO2.  
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Mice 
C57BL/6J, LysMcre [69] and OT-1 [85] mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Mice with a floxed Cebpa gene, called 
Cebpaflox/flox [70], were a gift from Peter Johnson (NCI, Frederick, MD). The 
animals were housed in pathogen-free units at the Vanderbilt University Medical 
Center, in compliance with IACUC regulations. We generated mice with myeloid-
specific deletion of Cebpa by breeding Cebpaflox/flox mice to LysMCre mice, which 
express Cre recombinase under the control of murine lysozyme M promoter. F1 
LysMCre+/-;Cebpafl/+ were then crossed to produce the genotypes used in the 
experiments. Mice used were between 6 and 10 weeks of age. The studies were 
approved by the Institutional Animal Care and Use Committee at Vanderbilt 
University Medical Center and complied with all relevant institutional and federal 
guidelines and policies. 
 
Tumor allograft model 
B16 or 3LL cells (1 x 105 cells), with or without Gr1+CD11b+ cells (1 x 104 
cells), were injected subcutaneously into the left flank of C57Bl/6 mice. The size 
of tumors was determined by measurement of tumor dimensions at 2–3 day 
intervals using calipers. The equation volume = length x (width)2 x 0.5 was used 
to calculate tumor volume. Tumor samples taken at days 21 (3LL) or 30 (B16) 
post-injection were flash frozen in Tissue-Tek OCT (Sakura, Torrance, CA) and 
prepared for histology. Experiments were repeated at least three times. 
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Single-cell sorting 
Single cell suspensions of splenocytes from tumor-bearing mice were stained 
with fluorescence-labeled Gr-1 (Cat. # 553126, monoclonal, rat) and CD11b (Cat. 
# 553311, monoclonal, rat) antibodies (BD Biosciences, San Jose, CA) for 15 
minutes at 0°C. Gr-1+CD11b+ cells were sorted with a BD FACSAria cell sorter 
in the VA or VUMC Flow Cytometry Resource and collected for tumor growth 
experiments. 
 
Immunohistochemistry 
Cryo-preserved tumor sections were blocked with M.O.M. solution (Vector 
Laboratories, Burlingame, CA), incubated with antibodies to CD31 (BD 
Biosciences, San Jose, CA; 1:500 dilution) overnight (4° C), and visualized by 
using Texas Red-conjugated goat anti-rat 2nd antibody (Jackson Immuno 
Research Laboratories, West Grove, PA; 1:10000 dilution). Images were 
captured with a fluorescent microscope. Vascular density was calculated in 10 
randomly selected fields and counted in a blinded manner. Average pixel density 
was measured with ImageJ software (http://rsb.info.nih.gov/ij/). These 
experiments were repeated 3 times. 
 
Enzyme activity 
NO production was measured as the product of NO3- and NO2- in culture 
media using a Nitrate/Nitrite Assay Kit (Alexsis Biochemicals, Farmingdale NY, 
Cat. # 850-001-KI01) according to manufacturer’s instructions. Assay was 
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performed in triplicate and repeated twice. 
 
Suppression of antigen-specific T-cell proliferation 
MDSCs magnetically purified from the tumors of myeloid conditional null mice 
and wild-type littermates were cultured with various ratios with OT-1 [85] 
splenocytes that had been labeled with CFSE (Molecular Probes, Eugene, OR) 
and activated with ovalbumin (Thermo Fisher Scientific, Pittsburg, PA, Cat. # 
BP2535-5; 125 ug/mL). After 4 days in culture, CFSE fluorescence was 
measured by flow cytometry. The average number of cell divisions was 
calculated [86] and plotted. Assay was performed in triplicate and repeated twice. 
 
Statistical Analysis 
 All data were averaged, analyzed using the Student’s t test (one-sided; 
paired, equal variance) and were expressed as mean ± standard error across 
experiments.  
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Results 
 
Conditional deletion of myeloid C/EBPα increases tumor growth 
C/EBPα has been identified as a tumor suppressor in multiple tissues based 
upon its role in inhibiting proliferation. Because of this and our finding that 
C/EBPα inhibits MDSC proliferation and expansion, we wanted to determine the 
role of myeloid C/EBPα in tumor growth. Toward that end, we injected 
Cebpaflox/flox;LysMCre+/+ conditional null mice and Cebpaflox/flox;LysMCre-/- 
littermates with 3LL tumors subcutaneously in the hindlimb. Tumor size was 
measured by caliper. We found that the tumor growth rate was significantly 
increased in C/EBPa myeloid conditional null mice compared to littermate 
controls (Figure 8A). We also inoculated mice with B16 melanoma cells and 
obtained similar results (Figure 8B). These results suggest a negative role for 
myeloid C/EBPα in tumor growth and progression. 
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Figure 8. Tumor growth is accelerated in C/EBPα conditional null mice. (A) Wild-
type (C/EBPαflox/flox, WT) and myeloid conditional null (C/EBPαflox/flox;LysMCre, CN) mice 
were injected with 1x 105 3LL (A) or B16 (B) tumor cells in the hindlimb. Tumor 
dimensions were measured every 2-3 days with caliper and tumor volume was 
calculated and plotted with time. * p < 0.05, n = 10 mice per group. The experiment was 
repeated 4 times. 
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Tumors from C/EBPα myeloid conditional null mice have increased MDSC 
infiltration and vascularization 
 MDSCs are known to infiltrate into tumors and modulate the tumor 
microenvironment to promote tumor progression [18]. We therefore compared 
MDSC infiltration in tumors harvested from Cebpaflox/flox;LysMCre+/+ and 
Cebpaflox/flox;LysMCre-/- littermates 21 days after inoculation with 3LL tumor cells. 
We stained tumor sections with anti-Gr-1 antibody (Figure 9A) and Gr1+ cells 
were counted as a measure of MDSC infiltration. We observed a significant 
increase in MDSC infiltration into the tumors of C/EBPα conditional null mice 
relative to littermate controls (Figure 9B).  
 It is well established that MDSCs directly promote tumor growth through 
increased tumor angiogenesis [18]. We next analyzed tumor vascular density by 
staining tumor sections harvested from both groups with an anti-CD31 antibody 
(Figure 9C) and counted CD31+ blood vessels. A significantly higher blood 
vessel density was observed in the tumors grown in C/EBPα conditional null mice 
than in controls (Figure 9D).  
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Figure 9. Tumors from C/EBPα conditional null mice have increased MDSC 
infiltration and vascularity. Size-matched tumors were harvested from myeloid 
conditional null (C/EBPαflox/flox;LysMCre, C/EBPα CN) and control littermate mice 
(C/EBPαflox/flox, WT), sectioned and stained with Gr-1 (A) or CD31 (C) fluorescent 
antibodies. Representative images are shown. The number Gr-1+ cells (B) and CD31+ 
vascular structures (D) were quantified in 10 randomly selected fields under microscopy. 
* p < 0.05. 
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MDSCs from C/EBPα conditional null mice have increased capacity to promote 
tumor growth  
We observed increased myeloid progenitor production in mice with a myeloid-
lineage deletion of C/EBPα. Upon inoculation of those mice with tumor cells, we 
observed greater MDSC expansion and infiltration into the tumors, increased 
tumor angiogenesis and accelerated tumor growth. We sought to determine if 
MDSCs were responsible for increased tumor angiogenesis and accelerated 
tumor growth in the conditional null animals. Additionally, we wanted to establish 
whether that effect was due solely to greater MDSC expansion in those mice. We 
next performed a reconstitution experiment where Gr1+CD11b+ cells were 
sorted from the spleens of Cebpaflox/flox;LysMCre+/+ (CN) and wild-type 
(Cebpaflox/flox;LysMCre-/-, WT) tumor-bearing littermates by FACS. We 
consistently achieved greater than 95% purity. Next, 1 x 104 purified 
Gr1+CD11b+ cells were mixed with 1 x 105 3LL tumor cells (1:10 ratio) and co-
injected subcutaneously into the flanks of C57BL/6 mice. C57BL/6 mice were 
also injected with tumor cells alone and tumor cells mixed with MDSCs isolated 
from wild-type mice as controls. Tumor size was measured with a caliper and 
tumor volume was calculated. As expected, the tumor growth rate was greater 
when tumor cells were co-injected with Gr1+CD11b+ MDSCs from wild-type 
tumor-bearing mice compared to tumor cells alone (Figure 10). Interestingly, 
when mice were injected with tumor cells mixed with Gr1+CD11b+ MDSCs from 
tumor-bearing Cebpaflox/flox;LysMCre+/+ mice, tumor growth was further 
accelerated (Figure 10). This led us to conclude that MDSCs contributed to the  
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Figure 10. MDSCs from C/EBPα conditional null mice promote tumor growth and 
angiogenesis. Wild-type (C/EBPαflox/flox, WT) and myeloid conditional null 
(C/EBPαflox/flox;LysMCre, CN) mice were injected with 1x 105 3LL tumor cells in the 
hindlimb. After 21 days, Gr-1+CD11b+ cells were purified from the spleens by FACS. 
Wild-type C57BL/6 mice were injected with 1x 105 3LL tumor cells or 3LL cells combined 
with 1x 104 Gr-1+CD11b+ cells from wild type (WT MDSC) or C/EBPα conditional null 
mice (CN MDSC). Tumor dimensions were measured every 2-3 days with caliper and 
tumor volume was calculated and plotted with time. * p < 0.05 (CN MDSC vs. WT 
MDSC), # p < 0.05 (CN MDSC vs. WT MDSC and 3LL alone). 
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increased angiogenesis and accelerated tumor growth we observed in 
Cebpaflox/flox;LysMCre+/+ mice. Since equal numbers of MDSCs were injected with 
tumor cells, the only difference was whether C/EBPα had been deleted in the 
MDSCs. We hypothesized that conditional C/EBPα deletion in 
Cebpaflox/flox;LysMCre+/+ mice had somehow enhanced MDSC tumor-promoting 
properties within the tumor microenvironment. 
 
MDSCs from C/EBPα conditional null mice have increased capacity to promote 
tumor angiogenesis 
Next we sought to determine if the accelerated tumor growth we observed in 
mice injected with MDSCs from Cebpaflox/flox;LysMCre+/+ mice was due to 
increased tumor angiogenesis. After an analysis of tumor vascularity by staining 
the tumor sections with CD31 antibody, we observed a significant increase in 
vascular density in the tumors co-injected with Gr1+CD11b+ MDSCs from 
Cebpaflox/flox;LysMCre+/+ mice compared with controls (Figure 11B). Furthermore, 
the blood vessels in tumors from mice co-injected with Gr1+CD11b+ MDSCs 
from tumor-bearing myeloid conditional null mice were bigger and had larger 
lumens (Figure 11A). These data collectively support dual roles of C/EBPα in 
MDSC biology; it negatively regulates MDSC expansion, as well as the pro-
angiogenic and pro-tumor activities of MDSCs.  
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Figure 11. MDSCs from C/EBPα conditional null mice promote tumor 
angiogenesis. Wild-type (C/EBPαflox/flox, WT) and myeloid conditional null 
(C/EBPαflox/flox;LysMCre, C/EBPα CN) mice were injected with 1x 105 3LL tumor cells in 
the hindlimb. After 21 days, Gr-1+CD11b+ cells were purified from the spleens by FACS. 
Wild-type C57BL/6 mice were injected with 1x 105 3LL tumor cells or 3LL cells combined 
with 1x 104 Gr-1+CD11b+ cells from wild type or C/EBPα conditional null mice. Tumors 
were harvested; sections were cut and stained with CD31 fluorescent antibody. 
Representative images are shown (A). The number CD31+ vascular structures were 
quantified in 5 randomly selected fields under microscopy (B, upper). CD31+ vascular 
area was quantified in 5 randomly selected fields as average pixel area using ImageJ (B, 
lower). * p < 0.05.
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C/EBPα negatively regulates angiogenic gene expression in MDSCs. 
MDSCs infiltrate into tumors and modulate the tumor microenvironment 
through production of growth factors and cytokines. Based on our findings that 
C/EBPα negatively regulates the angiogenic and tumor-promoting activities of 
MDSCs (Figure 11), we measured the expression of genes involved in MDSC-
mediated immune suppression and angiogenesis. MDSCs were purified from the 
spleens of tumor-bearing mice by magnetic cell sorting. We found that C/EBPα 
ablation resulted in increased the expression of inducible nitric oxide synthase 
(iNOS), with no effect on arginase 1 expression (Figure 12A). The production of 
nitric oxide, a mediator critical for immune suppressive functions of MDSCs as 
well as angiogenesis, was also significantly increased in Cebpaflox/flox;LysMCre+/+ 
(CN) MDSCs (Figure 12B). Additionally, we found that levels of MMP-9 and 
vascular endothelial growth factor A (VEGF-A), two important angiogenic 
mediators associated with MDSCs, were also significantly elevated in MDSCs 
from Cebpaflox/flox;LysMCre+/+ mice. Furthermore, overexpression of C/EBPα in 
32D cells resulted in decreased iNOS and VEGF-A expression when compared 
to vector control (Figure 12C). These data provide molecular evidence supporting 
a negative role of C/EBPα in the pro-angiogenic properties of MDSCs by 
inhibiting angiogenic gene expression. 
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Figure 12. C/EBPα negatively regulates angiogenic gene expression. Gr-1+CD11b+ 
MDSCs were magnetically purified from spleens of C/EBPα conditional null (CN) and WT 
littermate 3LL tumor bearing mice (n= 5 mice pooled together per group). RNA was 
isolated and arginase 1 (Arg1), inducible nitric oxide synthase 1 (iNOS), matrix 
metalloproteinase 9 (MMP-9) and VEGF-A expression was measured by real time PCR 
(A). Gr-1+CD11b+ MDSCs from tumor bearing mice were cultured for 3 days. Nitrate 
and nitrite production was measured in the culture supernatants with Nitrate/Nitrite 
Assay Kit and total NO production was calculated (B). 32D cells were transfected with a 
C/EBPα expression plasmid or vector control. RNA was isolated and arginase (Arg1), 
inducible nitric oxide synthase 1 (iNOS), matrix metalloproteinase 9 (MMP-9) and VEGF-
A expression was measured by real time PCR (C). *p < 0.05. The experiment was done 
in triplicate and repeated 3 times. 
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C/EBPα does not play a major role in MDSC-mediated immune suppression 
 Given the ability of MDSCs to suppress anti-tumor immune responses and 
our gene expression data, we wondered if C/EBPα regulates the immune-
suppressive function of MDSCs. We therefore performed an immune 
suppression assay. MDSCs were purified from the tumors of 
Cebpaflox/flox;LysMCre+/+ (CN) mice and littermate controls and cultured with 
activated splenocytes that had been labeled with CFSE. After a few days in 
culture, we quantified CFSE dilution on a flow cytometer as a measure of 
proliferation. We observed no difference in the ability to inhibit antigen-specific T-
cell proliferation between MDSDs from Cebpaflox/flox;LysMCre+/+ mice and 
littermate controls (Figure 13). We concluded that C/EBPα does not play a major 
role in MDSC-mediated immune suppression. 
 
	  
55 
0
10
20
30
40
1:1 1:2 1:4 1:6
!"
#$
%&
#'
('
)*
'+
#,
,'-
."
./.
)0
/'
1%2)')*'3456/758,#0)+9:#/'
!"#
$%#
 
 
Figure 13. C/EBPα does not play a major role in MDSC-mediated immune 
suppression. Gr-1+CD11b+ MDSCs were magnetically purified from spleens of 
C/EBPα conditional null (CN) and WT littermate 3LL tumor bearing mice (n=5 mice 
pooled together per group). OT-1 splenocytes labeled with CFSE and stimulated with 
ovalbumin were cultured with the purified MDSCs. CFSE fluorescence was measured 
and the number of cell divisions was calculated. Differences between WT and CN were 
not significant. This experiment was repeated twice. 
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Discussion 
MDSCs infiltrate into tumors where they promote tumor angiogenesis and 
suppress the host immune response to cancer. MDSCs from tumor-bearing mice 
have been shown to directly promote tumor angiogenesis and growth [18]. We 
observed that tumor growth was significantly accelerated in mice harboring a 
conditional deletion of C/EBPα in myeloid-lineage cells. Furthermore, the tumors 
had greater MDSC infiltration and increased vascular density. When MDSCs 
from mice with myeloid-lineage ablation of C/EBPα were combined with tumor 
cells in a co-injection study, tumor angiogenesis and growth was further 
increased. 
MDSCs promote tumor angiogenesis and tumor cell invasion through the 
production of MMP-9 and VEGF [18,40]. We found that the expression of MMP-9 
and VEGF was significantly increased in MDSCs purified from tumor-bearing 
C/EBPα conditional null mice. The immune suppressive properties of MDSCs are 
largely due to arginase and iNOS activity. Although we did not observe any 
difference in arginase expression, we observed that iNOS expression and activity 
was significantly greater in MDSCs isolated from tumor-bearing mice with a 
myeloid-lineage deletion of C/EBPα. In addition mediating the immune 
suppressive properties of MDSCs, NO also regulates angiogenesis [87]. 
Intriguingly, when we overexpressed C/EBPα in 32D myeloid cells, arginase 
expression was significantly reduced. This apparent discrepancy may be due to 
differences between primary cells and cell lines. Though a literature search 
yielded no reports of C/EBPα regulating arginase expression, the arginase 2 
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promoter does contain a predicted C/EBPα binding site. Additionally we observed 
no effect on MMP-9 expression when C/EBPα was overexpressed in 32D cells 
despite a modest but significant increase in its expression in MDSCs isolated 
C/EBPα conditional null mice. Although the human, mouse and rat MMP-9 
promoters have predicted C/EBPα binding sites, there are no reports of C/EBPα 
inhibiting MMP-9 expression.  
Regardless, the overexpression data did confirm our observations regarding 
iNOS and VEGF expression in C/EBPα null MDSCs. C/EBPα overproduction 
inhibited iNOS and VEGFA expression in the 32D myeloid cell line. The human 
iNOS and VEGFA promoters both contain confirmed C/EBPα binding sites. 
Furthermore, macrophages isolated from tumor-bearing mice display reduced 
C/EBPα binding to the iNOS promoter [88]. C/EBPα is also a negative regulator 
of VEGFA expression in the heart [89]. 
In order to rule out a role for C/EBPα in immune suppressive properties of 
MDSCs, we compared the ability to suppress T-cell proliferation between MDSCs 
purified from C/EBPα conditional null mice and littermate controls. We observed 
no difference between the groups and therefore, concluded that C/EBPα does 
not play a major role in MDSC-mediated immune suppression. The results 
suggest that, in addition to inhibiting MDSC expansion, C/EBPα also functions as 
a negative regulator of MDSC activation and function. Through the ability to 
repress iNOS and VEGF expression and NO production, C/EBPα inhibits the 
promotion of tumor angiogenesis in MDSCs. 
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CHAPTER IV 
 
PRELIMINARY DATA 
 
Materials and Methods 
 
Single-cell sorting 
Single cell suspensions of splenocytes from tumor-free mice were stained 
with fluorescence-labeled Gr-1 (Cat. # 553126, monoclonal, rat) and CD11b (Cat. 
# 553311, monoclonal, rat) antibodies (BD Biosciences, San Jose, CA) for 15 
minutes at 0°C. Gr-1+CD11b+ cells were sorted with a BD FACSAria cell sorter 
in the VA or VUMC Flow Cytometry Resource and collected for tumor growth 
experiments. 
 
Cell lines 
Lewis lung cancer (3LL) cell line (# CRL-1642) and B16 melanoma (# CRL-
6475) cell line (all murine, C57BL/6J mice) were purchased from ATCC 
(Manassas, VA). 3LL cells were grown in RPMI 1640 + 10% FBS + 1% 
penicillin/streptomycin at 37°C, 5% CO2.  
 
Mice 
C57BL/6J and LysMcre [69] mice were purchased from Jackson Laboratories 
(Bar Harbor, ME). Mice with a floxed Cebpa gene, called Cebpaflox/flox [70], were 
a gift from Peter Johnson (NCI, Frederick, MD). The animals were housed in 
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pathogen-free units at the Vanderbilt University Medical Center, in compliance 
with IACUC regulations. We generated mice with myeloid-specific deletion of 
Cebpa by breeding Cebpaflox/flox mice to LysMCre mice, which express Cre 
recombinase under the control of murine lysozyme M promoter. F1 LysMCre+/-
;Cebpafl/+ were then crossed to produce the genotypes used in the experiments. 
Mice used were between 6 and 10 weeks of age. The studies were approved by 
the Institutional Animal Care and Use Committee at Vanderbilt University Medical 
Center and complied with all relevant institutional and federal guidelines and 
policies. 
 
Tumor isograft model 
3LL cells (1 x 105 cells), with or without Gr1+CD11b+ cells (1 x 104 cells), 
were injected subcutaneously into the left flank of C57Bl/6 mice. The size of 
tumors was determined by measurement of tumor dimensions at 2–3 day 
intervals using calipers. The equation volume = length x (width)2 x 0.5 was used 
to calculate tumor volume. Experiments were repeated at least three times. 
 
Statistical Analysis 
 All data were averaged, analyzed using the Student’s t test (one-sided; 
paired, equal variance) and were expressed as mean ± standard error across 
experiments.  
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Results 
 
Gr-1+/CD11b+ cells from tumor-free C/EBPα conditional null mice promote tumor 
growth. 
Our finding that C/EBPa inhibits pro-angiogenic gene expression led us to 
wonder whether MDSCs isolated from tumor-free CN mice might also promote 
tumor growth. To that end, Gr-1+/CD11b+ cells were isolated from tumor-free 
C/EBPα conditional null mice by FACS. Since they were purified from normal 
mice, i.e. mice that did not have tumors, these Gr-1+/CD11b+ cells are not 
technically MDSCs [25]. Intriguingly however, when mixed with 3LL tumor cells 
(1:10) and injected into wild-type C57Bl/6 mice, they behaved liked MDSCs and 
tumor growth was significantly accelerated (Figure 14). This finding was obtained 
in a pilot experiment that must be repeated with control Gr-1+/CD11b+ cells from 
wild-type tumor free mice. With that caveat, this is the first instance to our 
knowledge of Gr-1+/CD11b+ cells from tumor-free mice phenotypically mimicking 
MDSCs. This data hints that C/EBPα may be key regulator of MDSCs biology.  
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Figure 14. Gr-1+/CD11b+ cells from tumor-free C/EBPα conditional null mice 
promote tumor growth. FACS-purified Gr-1+/CD11b+ cells from the spleens of 
C/EBPα conditional null mice were mixed with 1x 105 3LL tumor cells (1:10) and injected 
s.c. into the flanks of C57BL/6 mice (3LL+Gr1/CD11b). C57Bl/6 mice were injected with 
1x 105 3LL tumor cells as a control (3LL alone). Tumor dimensions were measured 
every 2-3 days with caliper and tumor volume was calculated and plotted with time.  
* p < 0.05, ** p < 0.01. 
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CHAPTER V 
 
CONCLUSION 
 
Summary 
 
In this work, we sought to elucidate the role of C/EBPα in regulating myeloid-
derived suppressor cell expansion and the pro-tumor activities of these cells. In 
Chapter II, we present evidence that C/EBPα is a negative regulator of MDSC 
expansion through its ability to inhibit proliferation. Deletion of myeloid C/EBPα in 
mice yielded an increase in myeloid progenitors, accompanied by a reduction in 
circulating monocytes. Upon inoculation with tumor cells, splenic MDSC 
production was enhanced nearly two-fold in mice lacking C/EBPα in myeloid 
lineage cells.  
In Chapter III, we give evidence that C/EBPα is a negative regulator of the 
pro-angiogenic properties of MDSCs. Conditional deletion of C/EBPα in myeloid 
lineage cells enhanced MDSC infiltration and tumor vascularization, resulting in 
markedly accelerated tumor growth in those mice. In an experiment where equal 
numbers of MDSCs were injected with tumor cells into mice, C/EBPα ablation 
resulted in an enhancement in the pro-tumor MDSC phenotype: tumor growth 
and tumor angiogenesis was significantly greater. In order to understand the 
mechanism behind our observation, we measured the expression genes involved 
in MDSC-mediated immune suppression and angiogenesis. We found that 
C/EBPα deletion resulted in upregulation of MMP-9, VEGF and iNOS expression, 
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as well as increased NO production. Additionally, overexpression of C/EBPα in 
myeloid cells caused a significant reduction in iNOS and VEGF expression. We 
did not, however, observe any difference in the ability to suppress T-cell 
proliferation. Given that NO can also regulate angiogenesis, we concluded that 
C/EBPα does not play a major role in MDSC-mediated immune suppression. 
The process of MDSC production begins in the bone marrow, where tumor-
produced or tumor-induced expansion signals initiate MDSC expansion. Many of 
the growth factors that normally induce myeloid progenitors to proliferate and 
mature, including granulocyte macrophage colony-stimulating factor (GM-CSF), 
macrophage colony-stimulating factor (M-CSF) and granulocyte colony-
stimulating factor (G-CSF), also serve as expansion signals for MDSCs in the 
bone marrow and spleen. Inflammatory molecules and cytokines such as IL-1β, 
IL-6 and PGE2 are also involved in MDSC expansion. These signals activate the 
JAK-STAT pathway and the STAT-3 transcription factor in particular. 
Interestingly, many of the receptors for these signals are C/EBPα target genes, 
including GM-CSFR, M-CSFR, G-CSFR and IL-6R, suggesting that C/EBPα 
initially may be required in the MDSC pathway.  
Tumor and stromal cells also secrete chemokines that recruit MDSCS from 
the bone marrow, spleen and liver to the tumor. This process involves multiple 
pathways, including CCL2-CCR2 and SDF-1-CXCR4 interactions. TNFα is also 
involved in MDSC recruitment and our data suggests that it may participate in 
down-regulation of C/EBPα in the spleen and tumor. Once MDSCs are recruited 
and infiltrate into tumors, numerous signals within the tumor microenvironment 
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activate MDSCs. Hypoxia signaling through HIF-1α is indispensible for MDSC 
activation. Other signals for MDSC activation include interferon-γ, IL-1B and stem 
cell factor. The hypoxic and inflammatory microenvironment strongly inhibits 
C/EBPα expression, allowing for increased MDSC proliferation and resulting in 
the up-regulation of MMP-9, NO and VEGFA production.  
The ability of MDSCs to promote tumor growth and metastasis has made 
uncovering the regulators of MDSC expansion and function a priority. While we 
have a good understanding of the molecules crucial for MDSC biology, much 
less is known about the negative regulation of MDSCs. A recent study 
determined that a micro-RNA, miR-223, suppresses accumulation of tumor-
induced CD11b+Gr1+ MDSCs [90]. This coincides with the data presented here, 
as miR-223 is a known C/EBPα target gene; C/EBPα up-regulates miR-223 
expression during granulocyte differentiation [91]. Another recent article identified 
interferon (IFN) regulatory factor 8 (IRF-8) as a potential inhibitor of MDSC 
production and demonstrated that modulation of IRF-8 levels in tumor-induced 
CD11b+Gr-1+ cells can significantly abrogate their pro-tumorigenic behavior [92]. 
IRF-8 is a hematopoietic transcription factor that facilitates myeloid differentiation 
[93]. Interestingly, forced IRF-8 expression in a model of CML, BCR/ABL-
transformed myeloid cells, specifically restored C/EBPα expression [94]. To our 
knowledge, this is the only report linking IRF-8 and C/EBPα expression and more 
work is needed to determine the specific role of these transcription factors in 
inhibiting MDSC expansion and activation.  
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A recent study indicated a critical role for C/EBPβ in the immune suppressive 
functions of MDSCs [29]. Marigo et al. provided evidence that hematopoietic 
deletion of C/EBPβ, a member of the same family of proteins as C/EBPα, led to a 
decrease in the number of MDSCs and a loss in the tolerance promoting 
activities of MDSCs, accompanied by a difference in the differentiation of myeloid 
cells [95]. Additionally, C/EBPδ regulates VEGFC signaling in lymphangiogenesis 
through HIF-1α [96]. These findings, along with our findings, point to important 
roles for this family of transcription factors in MDSC biology.  
An emerging model proposes that a shift from ‘steady-state’ hematopoiesis 
driven by transcription factors such as C/EBPα to transcription factors that 
promote inflammatory ‘emergency granulopoiesis,’ including C/EBPβ is 
necessary for MDSC maturation [97]. C/EBPα appears to function as an inhibitor 
of this process. Notably, C/EBPα activates the protease that cleaves full-length 
C/EBPβ to generate LIP (liver-enriched transcriptional inhibitory protein), a 
dominant-negative transcription inhibiting isoform [98]. Therefore, tumor-induced 
down-regulation of C/EBPα may be a required step in MDSC maturation and/or 
activation. This would simultaneously release the brakes on proliferation and 
activate angiogenesis-inducing VEGF and NO production. Additionally, reduced 
LIP conversion allows the active isoform of C/EBPβ critical for immune 
suppression to predominate. 
Therapeutic targeting of MDSCs in cancer and other pathological conditions 
is an area of intense and ongoing research. Recently proposed strategies include 
promoting myeloid-cell differentiation, inhibiting MDSC expansion, inhibiting 
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MDSC function and elimination of MDSCs [99]. Our work suggests that restoring 
C/EBPα expression in MDSCs may promote their differentiation while inhibiting 
MDSC expansion and function. The validity of this approach has already been 
demonstrated in the myeloid leukemia field, where reintroduction of C/EBPα in 
CD34+ leukemic cells impaired their self-renewal capacity and enhanced myeloid 
differentiation [100]. More promising is a recent report that nanoparticles were 
used to efficiently deliver C/EBPα to mesynchymal stem cells [101]. If successful, 
restoring C/EBPα expression could lead to fewer MDSCs in the tumor 
microenvironment due decreased MDSC proliferation. It could also result in 
MDSC differentiation into mature, functional immune cells able to recognize and 
destroy the tumor. Furthermore, it might also result in increased LIP generation 
and decreased C/EBPβ activity. When C/EBPβ was conditionally deleted in the 
hematopoietic system, the percentage of MDSCs was decreased [102]. This was 
accompanied by reduced arginase and NO production and the inability to 
suppress immune responses. Thus, it may be possible to reduce MDSC-
mediated immune suppression and angiogenesis, while increasing immune 
surveillance by reactivating or re-expressing C/EBPα in MDSCs. 
Taken together, our findings reveal dual negative roles for C/EBPα in the 
expansion and pro-angiogenic gene expression in MDSCs. Our work suggests 
that therapy aimed at restoring C/EBPa expression in MDSCs may be promising 
and effective in the treatment of solid tumors. 
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Future Directions 
 
Our finding that C/EBPa inhibits pro-angiogenic gene expression led us to 
wonder whether Gr-1+/CD11b+ isolated from tumor-free C/EBPα conditional null 
mice might also promote tumor growth. To that end, wild-type C57Bl/6 mice were 
injected with either Gr-1+/CD11b+ cells isolated from tumor-free C/EBPα 
conditional null mice mixed with 3LL tumor cells (1:10) or tumor cells alone. 
Intriguingly, we found that Gr-1+/CD11b+ cells from tumor-free CN mice, when 
mixed with tumor cells, promote tumor growth and tumor growth was significantly 
accelerated in those mice. Thus, conditionally deleting C/EBPα in myeloid cells 
from tumor-free mice produces Gr-1+/CD11b+ cells that phenotypically mimic 
MDSCs in tumor-bearing mice.  
Our preliminary data suggests that C/EBPα may be a key regulator of MDSC 
biology. However, this finding was obtained in a pilot experiment and must be 
confirmed with control Gr-1+/CD11b+ cells from wild-type tumor-free mice. If 
C/EBPα is a key regulator of MDSC biology, it is expected that conditional 
C/EBPα deletion in Gr-1+/CD11b+ cells might phenocopy the pro-tumor activities 
of MDSCs. To confirm this, tumor size and growth rate could be compared 
between wild-type mice injected with tumor cells alone, tumor cells mixed with 
Gr-1+/CD11b+ cells from tumor-free wild-type or C/EBPα conditional null mice, 
and tumor cells mixed with MDSCs from tumor-bearing wild-type or C/EBPα 
conditional null mice. The number and percentage of MDSCs in tumor tissues 
could be measured with flow cytometry and compared between the experimental 
 
	  
68 
groups. It would be particularly interesting to compare the tumor-promoting 
phenotype of Gr-1+/CD11b+ cells from tumor-free C/EBPα conditional null mice 
with that of MDSCs from wild-type and null tumor-bearing mice. Additionally, 
MDSC infiltration and vascular density could be measured in tumor sections from 
those mice to determine if Gr-1+/CD11b+ cells from C/EBPα null mice 
phenocopy the ability of MDSCs to infiltrate into tumors and promote tumor 
angiogenesis. Finally iNOS, MMP-9 and VEGF expression could be measured by 
real-time PCR in Gr-1+/CD11b+ cells isolated from C/EBPα null mice and 
compared with MDSCs from tumor-bearing mice. 
We hypothesize that the mechanism behind the ability of Gr-1+/CD11b+ cells 
to promote tumor growth is similar to that of MDSCs lacking C/EBPα, namely the 
capacity of C/EBPα to inhibit MDSC expansion and negatively regulate MMP-9 
and VEGF expression in MDSCs. As in MDSCs with C/EBPα ablation, Gr-
1+/CD11b+ cells with reduced C/EBPα expression are expected to have 
increased proliferative capacity and greater expression of MMP-9 and VEGF. To 
test this, one could measure and compare BrdU incorporation between MDSCs 
from wild-type and C/EBPα null tumor bearing and tumor-free mice. We could 
also compare MMP-9 activity by zymography and assay the net effect of MMP-9 
and VEGF expression by performing a VEGF ELISA on tumor tissues from wild-
type and C/EBPα null mice. 
To determine whether increased VEGF bioavailability in the C/EBPα null 
tumors is responsible for increased tumor growth, in vitro angiogenic assays 
could be performed with a VEGF inhibitor. MDSCs isolated from tumor tissues of 
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wild type or C/EBPα null mice are cultivated overnight. Endothelial cells, 
(HUVECs) are cultivated in the conditioned media from the MDSCs with or 
without a VEGF inhibitor or neutralizing antibody on Matrigel, allowing vascular 
tube structures to form. Branch points are counted at various intervals. One could 
also perform Boyden chamber migration assays to assess the ability of 
endothelial cells to migrate towards wild type and null MDSCs. For this assay, 
MDSCs are isolated from the tumor tissues of wild type and C/EBPα myeloid null 
mice and cultivated overnight. Then, HUVECs are placed in the top of a Boyden 
chamber with or without a VEGF inhibitor or neutralizing antibody and allowed to 
migrate toward the bottom chamber containing the MDSCs for 3.5 hours.  
Recent studies have reported that C/EBPα expression is reduced in a number 
of human cancers [78,103-109]. Additionally, mutations in the C/EBPα gene and 
disruptions in its function have been observed in a majority of acute myeloid 
leukemias [43,110-112], a cancer of myeloid lineage blood cells characterized by 
the aberrant accumulation of immature myeloid cells. Loss of C/EBPα function in 
myeloid progenitor cells results in a block of differentiation and deregulated 
proliferation, which are characteristic features of AML [113]. The similarity 
between AML cells and MDSCs and the observation of C/EBPα down-regulation 
in human cancers suggests that C/EBPα expression may be reduced in MDSCs 
from human cancer patients. Humans lack the Gr-1 gene, making MDSCs more 
difficult to define phenotypically human cancer patients. As a result, studies have 
reported many different markers for human MDSCs. However, the consensus is 
that human MDSCs express the myeloid markers CD11b and CD33 with no or 
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minimal expression of myeloid maturation markers [27]. It would be interesting to 
measure C/EBPα expression and protein levels in MDSCs purified from the 
peripheral blood of human cancer patients and compare it to tumor-free 
individuals. 
Given that C/EBPα is a transcription factor, it would be interesting to 
determine if it regulates the expression of known MDSC genes/cytokines. This 
could be investigated with 2 approaches. First, a cytokine array could be 
performed comparing MDSCs isolated from WT and null tumor bearing mice and 
the results could be confirmed with real-time PCR. Additionally, C/EBPα is 
regulated by and/or regulates the expression of a number of genes that have 
been demonstrated to play a role in MDSC biology, including IL-23, IRF-8, NF-
κB, STAT-1, STAT-3 and TGF-β. The expression of these genes could be 
measured by real-time PCR and compared between MDSCs from wild-type and 
conditional null mice. C/EBPα could also be overexpressed in myeloid cell lines 
and gene expression measured and compared to vector control. This approach 
may even be possible in MDSCs as technology allowing their isolation and 
culture improves.  
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Final remarks 
 
 In conclusion, this body of work established the important role of C/EBPα in 
MDSC biology and cancer growth and progression. It identified C/EBPα as a 
negative regulator of both MDSC expansion and MDSC function. C/EBPα 
suppresses MDSC production by inhibiting proliferation in myeloid progenitors 
and MDSCs. As a transcription factor, it inhibits pro-angiogenic gene expression 
in MDSCs. Therapeutic activation of this pathway in cancer could promote MDSC 
differentiation and decreased angiogenesis, resulting in delayed or halted tumor 
progression.  
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